{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:07:36Z","timestamp":1791936456328,"version":"4.3.4"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Liquid biopsy offers a noninvasive method to identify and monitor tumor-derived biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, microRNAs, and tumor-educated platelets, that provide real-time insights into the biological behavior of gynecological cancers. The detection of these markers has the potential to revolutionize cancer management by enabling earlier detection, providing novel data to personalize treatments, and predicting disease recurrence before clinical imaging can confirm progression, thereby also guiding complex clinical decision-making. However, because this new \u201comics\u201d layer introduces additional complexity, it must be fully understood, from its biological rationale to technical development and clinical integration, to prevent confusion or misapplication. That is why, focusing on 14 critical fields of inquiry, our goal is to map the current state of liquid biopsy from bench to bedside while highlighting practical considerations for clinical integration. Each topic integrates recent advances in assay sensitivity, biomarker variability, and data interpretation, underscoring how standardized protocols and robust analytical methods are pivotal for reliable results. We then translate these findings into disease-specific insights, examining how liquid biopsy could refine early detection, minimal residual disease assessment, and therapy guidance in endometrial, cervical, and ovarian cancers. Although several FDA-approved assays and promising commercial tests illustrate the field\u2019s rapid evolution, many translational hurdles remain, including the need for harmonized protocols, larger prospective clinical trials, and cost-effectiveness analyses. Crucially, our synthesis clarifies the pivotal role of interdisciplinary collaboration. Oncologists, laboratory scientists, and industry partners must align on standardized procedures and clinically relevant endpoints. Without such coordination, promising biomarkers may remain confined to research settings, limiting their practical benefit. Taken together, our review offers a translational view designed to contextualize liquid biopsy in gynecological oncology.<\/jats:p>","DOI":"10.1186\/s13046-025-03371-1","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T23:03:02Z","timestamp":1746658982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice"],"prefix":"10.1186","volume":"44","author":[{"given":"Canio","family":"Martinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ercoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon Raffaella","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrunda","family":"Satasiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Housem","family":"Kacem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Braccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Mazzarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Miriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Nana","family":"Tchamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Restaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Arcieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Tius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pergolizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Iat\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Conti","family":"Nibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pizzimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cortellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"3371_CR1","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2024 Dec 30]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): U.S. 2021 cancer prevalence estimates are based on 2021 cancer prevalence proportions from the SEER 12 Areas (excluding the Alaska Native Tumor Registry) and 1\/1\/2021 U.S. population estimates based on the average of 2020 and 2021 population estimates from the U.S. Bureau of the Census."},{"issue":"16","key":"3371_CR2","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1158\/1078-0432.CCR-17-0454","volume":"23","author":"H Husain","year":"2017","unstructured":"Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, et al. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017Aug 15;23(16):4716\u201323.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3371_CR3","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/1878-0261.12574","volume":"13","author":"S Villatoro","year":"2019","unstructured":"Villatoro S, Mayo-de-las-Casas C, Jordana-Ariza N, Viteri-Ram\u00edrez S, Garz\u00f3n-Iba\u00f1ez M, Moya-Horno I, et al. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. Mol Oncol. 2019Dec;13(12):2633\u201345.","journal-title":"Mol Oncol"},{"issue":"3","key":"3371_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4143\/crt.2019.700","volume":"52","author":"MR Han","year":"2020","unstructured":"Han MR, Lee SH, Park JY, Hong H, Ho JY, Hur SY, et al. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer. Cancer Res Treat. 2020Jul 15;52(3):779\u201388.","journal-title":"Cancer Res Treat"},{"issue":"7741","key":"3371_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","volume":"565","author":"AM Miller","year":"2019","unstructured":"Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019Jan;565(7741):654\u20138.","journal-title":"Nature"},{"issue":"8","key":"3371_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.adaj.2023.05.006","volume":"154","author":"T Nonaka","year":"2023","unstructured":"Nonaka T, Wong DTW. Saliva diagnostics. J Am Dent Assoc. 2023Aug;154(8):696\u2013704.","journal-title":"J Am Dent Assoc"},{"issue":"1","key":"3371_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","volume":"21","author":"SN Lone","year":"2022","unstructured":"Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022Mar 18;21(1):79.","journal-title":"Mol Cancer"},{"issue":"sup2","key":"3371_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2144\/000112749","volume":"44","author":"SH Curry","year":"2008","unstructured":"Curry SH. Translational Science: Past, Present, and Future. Biotechniques. 2008Feb;44(sup2):1.","journal-title":"Biotechniques"},{"issue":"1","key":"3371_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1057\/s41599-023-02597-8","volume":"11","author":"EMR Smith","year":"2024","unstructured":"Smith EMR, Molldrem S, Farroni JS, Tumilty E. Articulating the social responsibilities of translational science. Humanit Soc Sci Commun. 2024Jan 9;11(1):85.","journal-title":"Humanit Soc Sci Commun"},{"issue":"19","key":"3371_CR10","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.7150\/thno.34070","volume":"9","author":"L Tong","year":"2019","unstructured":"Tong L, Ding N, Tong X, Li J, Zhang Y, Wang X, et al. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019;9(19):5532\u201341.","journal-title":"Theranostics"},{"issue":"2","key":"3371_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3324\/haematol.2019.241208","volume":"106","author":"S Bobillo","year":"2020","unstructured":"Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2020Feb 20;106(2):513\u201321.","journal-title":"Haematologica"},{"issue":"6","key":"3371_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1258\/acb.2009.009002","volume":"46","author":"H Goldshtein","year":"2009","unstructured":"Goldshtein H, Hausmann MJ, Douvdevani A. A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids. Ann Clin Biochem Int J Lab Med. 2009Nov;46(6):488\u201394.","journal-title":"Ann Clin Biochem Int J Lab Med"},{"key":"3371_CR13","doi-asserted-by":"publisher","unstructured":"Millholland JM, Li S, Fernandez CA, Shuber AP. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Res Rep Urol. 2012;4:33-40. https:\/\/doi.org\/10.2147\/RRU.S32736.","DOI":"10.2147\/RRU.S32736"},{"issue":"5","key":"3371_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/cdd.2015.164","volume":"23","author":"M Martin","year":"2016","unstructured":"Martin M, Leffler J, Smol\u0105g KI, Mytych J, Bj\u00f6rk A, Chaves LD, et al. Factor H uptake regulates intracellular C3 activation during apoptosis and decreases the inflammatory potential of nucleosomes. Cell Death Differ. 2016May;23(5):903\u201311.","journal-title":"Cell Death Differ"},{"issue":"3","key":"3371_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.38265","volume":"66","author":"F Stephan","year":"2014","unstructured":"Stephan F, Marsman G, Bakker LM, Bulder I, Stavenuiter F, Aarden LA, et al. Cooperation of Factor VII\u2013Activating Protease and Serum DNase I in the Release of Nucleosomes From Necrotic Cells. Arthritis Rheumatol. 2014Mar;66(3):686\u201393.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3371_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1039\/C3LC50644D","volume":"14","author":"C Alix-Panabi\u00e8res","year":"2014","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Technologies for detection of circulating tumor cells: facts and vision. Lab Chip. 2014;14(1):57\u201362.","journal-title":"Lab Chip"},{"issue":"12","key":"3371_CR17","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1182\/blood-2008-06-159541","volume":"113","author":"G Lakka Klement","year":"2009","unstructured":"Lakka Klement G, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, et al. Platelets actively sequester angiogenesis regulators. Blood. 2009Mar 19;113(12):2835\u201342.","journal-title":"Blood"},{"issue":"5","key":"3371_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1752-8062.2010.00226.x","volume":"3","author":"DC Calverley","year":"2010","unstructured":"Calverley DC, Phang TL, Choudhury QG, Gao B, Oton AB, Weyant MJ, et al. Significant Downregulation of Platelet Gene Expression in Metastatic Lung Cancer. Clin Transl Sci. 2010Oct;3(5):227\u201332.","journal-title":"Clin Transl Sci"},{"issue":"13","key":"3371_CR19","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1182\/blood-2011-03-344408","volume":"118","author":"RJA Nilsson","year":"2011","unstructured":"Nilsson RJA, Balaj L, Hulleman E, Van Rijn S, Pegtel DM, Walraven M, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood. 2011Sep 29;118(13):3680\u20133.","journal-title":"Blood"},{"issue":"5","key":"3371_CR20","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","volume":"28","author":"MG Best","year":"2015","unstructured":"Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 2015Nov;28(5):666\u201376.","journal-title":"Cancer Cell"},{"issue":"6","key":"3371_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","volume":"30","author":"A Becker","year":"2016","unstructured":"Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. Cancer Cell. 2016Dec;30(6):836\u201348.","journal-title":"Cancer Cell"},{"issue":"1","key":"3371_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21873\/cgp.20015","volume":"14","author":"UH Weidle","year":"2017","unstructured":"Weidle UH, Birzele F, Kollmorgen G, R\u00fcger R. The Multiple Roles of Exosomes in Metastasis. Cancer Genomics Proteomics. 2017Jan 1;14(1):1\u201316.","journal-title":"Cancer Genomics Proteomics"},{"issue":"4","key":"3371_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2014.03.007","volume":"25","author":"W Zhou","year":"2014","unstructured":"Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. Cancer Cell. 2014Apr;25(4):501\u201315.","journal-title":"Cancer Cell"},{"issue":"2","key":"3371_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ijc.30669","volume":"141","author":"D Bach","year":"2017","unstructured":"Bach D, Hong J, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer. 2017Jul 15;141(2):220\u201330.","journal-title":"Int J Cancer"},{"key":"3371_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.canlet.2018.02.002","volume":"420","author":"R Bhome","year":"2018","unstructured":"Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE, et al. Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Lett. 2018Apr;420:228\u201335.","journal-title":"Cancer Lett"},{"issue":"21","key":"3371_CR26","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1039\/C7LC00592J","volume":"17","author":"JC Contreras-Naranjo","year":"2017","unstructured":"Contreras-Naranjo JC, Wu HJ, Ugaz VM. Microfluidics for exosome isolation and analysis: enabling liquid biopsy for personalized medicine. Lab Chip. 2017;17(21):3558\u201377.","journal-title":"Lab Chip"},{"issue":"1","key":"3371_CR27","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016Jan 28;1(1):15004.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"3371_CR28","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1002\/jcp.26481","volume":"233","author":"M Salehi","year":"2018","unstructured":"Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities. J Cell Physiol. 2018Sep;233(9):6370\u201380.","journal-title":"J Cell Physiol"},{"issue":"10","key":"3371_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1134\/S0006297920100065","volume":"85","author":"NV Vorobjeva","year":"2020","unstructured":"Vorobjeva NV, Chernyak BV. NETosis: Molecular Mechanisms, Role in Physiology and Pathology. Biochem Mosc. 2020Oct;85(10):1178\u201390.","journal-title":"Biochem Mosc"},{"issue":"11","key":"3371_CR30","doi-asserted-by":"publisher","first-page":"8226","DOI":"10.1074\/jbc.275.11.8226","volume":"275","author":"P Widlak","year":"2000","unstructured":"Widlak P, Li P, Wang X, Garrard WT. Cleavage Preferences of the Apoptotic Endonuclease DFF40 (Caspase-activated DNase or Nuclease) on Naked DNA and Chromatin Substrates. J Biol Chem. 2000Mar;275(11):8226\u201332.","journal-title":"J Biol Chem"},{"issue":"2","key":"3371_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ajhg.2020.01.008","volume":"106","author":"DSC Han","year":"2020","unstructured":"Han DSC, Ni M, Chan RWY, Chan VWH, Lui KO, Chiu RWK, et al. The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. Am J Hum Genet. 2020Feb;106(2):202\u201314.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"3371_CR32","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018Nov 29;9(1):5068.","journal-title":"Nat Commun"},{"issue":"7761","key":"3371_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019Jun;570(7761):385\u20139.","journal-title":"Nature"},{"issue":"S13","key":"3371_CR34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-2164-16-S13-S1","volume":"16","author":"M Ivanov","year":"2015","unstructured":"Ivanov M, Baranova A, Butler T, Spellman P, Mileyko V. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics. 2015Dec;16(S13):S1.","journal-title":"BMC Genomics"},{"issue":"1","key":"3371_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41525-018-0069-0","volume":"3","author":"C Sanchez","year":"2018","unstructured":"Sanchez C, Snyder MW, Tanos R, Shendure J, Thierry AR. New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis. Npj Genomic Med. 2018Nov 23;3(1):31.","journal-title":"Npj Genomic Med"},{"key":"3371_CR36","doi-asserted-by":"crossref","unstructured":"Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, et al. Fragment Length of Circulating Tumor DNA. Kwiatkowski DJ, editor. PLOS Genet. 2016;12(7):e1006162.","DOI":"10.1371\/journal.pgen.1006162"},{"issue":"1","key":"3371_CR37","doi-asserted-by":"publisher","first-page":"1505403","DOI":"10.1080\/20013078.2018.1505403","volume":"7","author":"T Vagner","year":"2018","unstructured":"Vagner T, Spinelli C, Minciacchi VR, Balaj L, Zandian M, Conley A, et al. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018Dec;7(1):1505403.","journal-title":"J Extracell Vesicles"},{"issue":"6","key":"3371_CR38","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1182\/blood-2012-02-412197","volume":"120","author":"TA Fuchs","year":"2012","unstructured":"Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, L\u00e4mmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012Aug 9;120(6):1157\u201364.","journal-title":"Blood"},{"issue":"8","key":"3371_CR39","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","volume":"20","author":"A Kustanovich","year":"2019","unstructured":"Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019Aug 3;20(8):1057\u201367.","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"3371_CR40","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.7150\/thno.18588","volume":"7","author":"L Chen","year":"2017","unstructured":"Chen L, Bode AM, Dong Z. Circulating Tumor Cells: Moving Biological Insights into Detection. Theranostics. 2017;7(10):2606\u201319.","journal-title":"Theranostics"},{"key":"3371_CR41","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz M, Pastuszak K, \u0141api\u0144ska-Szumczyk S, R\u00f3\u017ca\u0144ski R, Veld SGJGI \u2018t, Bie\u0144kowski M, et al. Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer. Cancers. 2021;13(22):5731.","DOI":"10.3390\/cancers13225731"},{"issue":"241","key":"3371_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154267","volume":"1","author":"D Patel","year":"2023","unstructured":"Patel D, Thankachan S, Sreeram S, Kavitha KP, Suresh PS. The role of tumor-educated platelets in ovarian cancer: A comprehensive review and update. Pathol - Res Pract. 2023Jan;1(241): 154267.","journal-title":"Pathol - Res Pract"},{"issue":"1","key":"3371_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13148-022-01337-0","volume":"14","author":"P Li","year":"2022","unstructured":"Li P, Liu S, Du L, Mohseni G, Zhang Y, Wang C. Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer. Clin Epigenetics. 2022Dec;14(1):118.","journal-title":"Clin Epigenetics"},{"issue":"4","key":"3371_CR44","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/cancers13040838","volume":"13","author":"XM Guo","year":"2021","unstructured":"Guo XM, Miller H, Matsuo K, Roman LD, Salhia B. Circulating Cell-Free DNA Methylation Profiles in the Early Detection of Ovarian Cancer: A Scoping Review of the Literature. Cancers. 2021Feb 17;13(4):838.","journal-title":"Cancers"},{"issue":"19","key":"3371_CR45","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.3390\/cancers14194818","volume":"14","author":"RD Neal","year":"2022","unstructured":"Neal RD, Johnson P, Clarke CA, Hamilton SA, Zhang N, Kumar H, et al. Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers. 2022Oct 1;14(19):4818.","journal-title":"Cancers"},{"issue":"1","key":"3371_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12958-021-00860-8","volume":"19","author":"F Yang","year":"2021","unstructured":"Yang F, Tang J, Zhao Z, Zhao C, Xiang Y. Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reprod Biol Endocrinol. 2021Dec 3;19(1):178.","journal-title":"Reprod Biol Endocrinol"},{"issue":"6378","key":"3371_CR47","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018Feb 23;359(6378):926\u201330.","journal-title":"Science"},{"key":"3371_CR48","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.ygyno.2024.07.301","volume":"190","author":"M Toboni","year":"2024","unstructured":"Toboni M, Maxwell L, Scalise CB, Berman T, Hardesty M, Ketch P, et al. Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring among patients with advanced or recurrent endometrial cancer. Gynecol Oncol. 2024Nov;190:S208\u20139.","journal-title":"Gynecol Oncol"},{"issue":"24","key":"3371_CR49","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1158\/1078-0432.CCR-24-2105","volume":"30","author":"P Soberanis Pina","year":"2024","unstructured":"Soberanis Pina P, Clemens K, Bubie A, Grant B, Haynes G, Zhang N, et al. Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer. Clin Cancer Res. 2024Dec 16;30(24):5657\u201365.","journal-title":"Clin Cancer Res"},{"key":"3371_CR50","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/j.ygyno.2023.06.221","volume":"176","author":"T Castellano","year":"2023","unstructured":"Castellano T, Bae-Jump V, Secord AA, Danziger N, Graf R, Quintanilha JCF, et al. Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320). Gynecol Oncol. 2023Sep;176:S194\u20135.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"3371_CR51","doi-asserted-by":"publisher","first-page":"1104659","DOI":"10.3389\/fonc.2023.1104659","volume":"27","author":"S Pinet","year":"2023","unstructured":"Pinet S, Durand S, Perani A, Darnaud L, Amadjikpe F, Yon M, et al. Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital. Front Oncol. 2023Feb;27(13):1104659.","journal-title":"Front Oncol"},{"issue":"1","key":"3371_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12938-021-00857-9","volume":"20","author":"LJ Galv\u00e3o-Lima","year":"2021","unstructured":"Galv\u00e3o-Lima LJ, Morais AHF, Valentim RAM, Barreto EJSS. miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. Biomed Eng OnLine. 2021Dec;20(1):21.","journal-title":"Biomed Eng OnLine"},{"issue":"19","key":"3371_CR53","doi-asserted-by":"publisher","first-page":"8292","DOI":"10.3390\/s23198292","volume":"23","author":"N Ramnauth","year":"2023","unstructured":"Ramnauth N, Neubarth E, Makler-Disatham A, Sher M, Soini S, Merk V, et al. Development of a Microfluidic Device for Exosome Isolation in Point-of-Care Settings. Sensors. 2023Oct 7;23(19):8292.","journal-title":"Sensors"},{"issue":"6","key":"3371_CR54","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41551-021-00746-5","volume":"5","author":"N Liang","year":"2021","unstructured":"Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T, et al. Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021Jun 15;5(6):586\u201399.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"3371_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-022-01588-8","volume":"21","author":"JW Zhu","year":"2022","unstructured":"Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer. Mol Cancer. 2022Dec;21(1):114.","journal-title":"Mol Cancer"},{"issue":"2","key":"3371_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1515\/cclm-2017-0019","volume":"56","author":"L Giannopoulou","year":"2018","unstructured":"Giannopoulou L, Kasimir-Bauer S, Lianidou ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Clin Chem Lab Med CCLM. 2018Jan 26;56(2):186\u201397.","journal-title":"Clin Chem Lab Med CCLM"},{"issue":"1","key":"3371_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tjog.2021.11.008","volume":"61","author":"HJ Jou","year":"2022","unstructured":"Jou HJ, Ling PY, Hsu HT. Circulating tumor cells as a \u201creal-time liquid biopsy\u201d: Recent advances and the application in ovarian cancer. Taiwan J Obstet Gynecol. 2022Jan;61(1):34\u20139.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"3","key":"3371_CR58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/biom13030428","volume":"13","author":"S Francini","year":"2023","unstructured":"Francini S, Duraes M, Rathat G, Macioce V, Mollevi C, Pages L, et al. Circulating Tumor Cell Detection by Liquid Biopsy during Early-Stage Endometrial Cancer Surgery: A Pilot Study. Biomolecules. 2023Feb 24;13(3):428.","journal-title":"Biomolecules"},{"issue":"9","key":"3371_CR59","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.3390\/ijms24097811","volume":"24","author":"D Kodada","year":"2023","unstructured":"Kodada D, Hyblova M, Krumpolec P, Janostiakova N, Barath P, Grendar M, et al. The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study. Int J Mol Sci. 2023Apr 25;24(9):7811.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3371_CR60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12032-023-01956-4","volume":"40","author":"Y Shen","year":"2023","unstructured":"Shen Y, Shi R, Zhao R, Wang H. Clinical application of liquid biopsy in endometrial carcinoma. Med Oncol. 2023Feb 9;40(3):92.","journal-title":"Med Oncol"},{"issue":"1","key":"3371_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13046-018-0688-4","volume":"37","author":"E Vizza","year":"2018","unstructured":"Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, Baiocco E, et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J Exp Clin Cancer Res. 2018Dec;37(1):16.","journal-title":"J Exp Clin Cancer Res"},{"key":"3371_CR62","doi-asserted-by":"crossref","unstructured":"Tong Y, Jia L, Li M, Li H, Wang S. Identification of exosomal circSLC26A4 as a liquid biopsy marker for cervical cancer. Cobucci RNO, editor. PLOS ONE. 2024;19(6):e0305050.","DOI":"10.1371\/journal.pone.0305050"},{"issue":"3","key":"3371_CR63","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e32","volume":"30","author":"YM Kim","year":"2019","unstructured":"Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE, Choi EK. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. J Gynecol Oncol. 2019;30(3): e32.","journal-title":"J Gynecol Oncol"},{"key":"3371_CR64","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Herrero E, Serna-Blasco R, Robado De Lope L, Gonz\u00e1lez-Rumayor V, Romero A, Provencio M. Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Front Oncol. 2022;12:943253.","DOI":"10.3389\/fonc.2022.943253"},{"key":"3371_CR65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","volume":"468","author":"DB Asante","year":"2020","unstructured":"Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Cancer Lett. 2020Jan;468:59\u201371.","journal-title":"Cancer Lett"},{"issue":"6","key":"3371_CR66","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/genes15060750","volume":"15","author":"T Senturk Kirmizitas","year":"2024","unstructured":"Senturk Kirmizitas T, Van Den Berg C, Boers R, Helmijr J, Makrodimitris S, Dag HH, et al. Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients. Genes. 2024Jun 7;15(6):750.","journal-title":"Genes"},{"issue":"18","key":"3371_CR67","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-23-0797","volume":"29","author":"S Lheureux","year":"2023","unstructured":"Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, et al. Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. Clin Cancer Res. 2023Sep 15;29(18):3706\u201316.","journal-title":"Clin Cancer Res"},{"key":"3371_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.11.012","volume":"125","author":"M Rusan","year":"2020","unstructured":"Rusan M, Andersen RF, Jakobsen A, Steffensen KD. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 2020Jan;125:121\u20139.","journal-title":"Eur J Cancer"},{"issue":"7447","key":"3371_CR69","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12065","volume":"497","author":"M Murtaza","year":"2013","unstructured":"Murtaza M, Dawson SJ, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013May;497(7447):108\u201312.","journal-title":"Nature"},{"key":"3371_CR70","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med [Internet]. 2014 Feb 19 [cited 2025 Jan 4];6(224). Available from: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.3007094"},{"issue":"18","key":"3371_CR71","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.3390\/cancers16183117","volume":"16","author":"A Golara","year":"2024","unstructured":"Golara A, Koz\u0142owski M, Cymbaluk-P\u0142oska A. The Role of Circulating Tumor DNA in Ovarian Cancer. Cancers. 2024Sep 10;16(18):3117.","journal-title":"Cancers"},{"issue":"9","key":"3371_CR72","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12032-023-02128-0","volume":"40","author":"F Karimi","year":"2023","unstructured":"Karimi F, Azadbakht O, Veisi A, Sabaghan M, Owjfard M, Kharazinejad E, et al. Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis. Med Oncol. 2023Aug 10;40(9):265.","journal-title":"Med Oncol"},{"issue":"8","key":"3371_CR73","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/10408363.2023.2230290","volume":"60","author":"A Ntzifa","year":"2023","unstructured":"Ntzifa A, Lianidou E. Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis. Crit Rev Clin Lab Sci. 2023Nov 17;60(8):573\u201394.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3371_CR74","doi-asserted-by":"publisher","first-page":"107327482412555","DOI":"10.1177\/10732748241255548","volume":"31","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhou N, Liu J. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation. Cancer Control. 2024Jan;31:10732748241255548.","journal-title":"Cancer Control"},{"issue":"1","key":"3371_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10787-022-01115-7","volume":"31","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi S, Tehrani FR, Tahmasebi S, Shafiee A, Hashemi SM. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology. 2023Feb;31(1):145\u201369.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"3371_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","volume":"21","author":"D Yu","year":"2022","unstructured":"Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022Dec;21(1):56.","journal-title":"Mol Cancer"},{"key":"3371_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117746","volume":"554","author":"K Anitha","year":"2024","unstructured":"Anitha K, Posinasetty B, Naveen Kumari K, Chenchula S, Padmavathi R, Prakash S, et al. Liquid biopsy for precision diagnostics and therapeutics. Clin Chim Acta. 2024Feb;554: 117746.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"3371_CR78","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41416-023-02423-7","volume":"129","author":"JM Cameron","year":"2023","unstructured":"Cameron JM, Sala A, Antoniou G, Brennan PM, Butler HJ, Conn JJA, et al. A spectroscopic liquid biopsy for the earlier detection of multiple cancer types. Br J Cancer. 2023Nov 9;129(10):1658\u201366.","journal-title":"Br J Cancer"},{"issue":"12","key":"3371_CR79","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.3390\/ijms22126501","volume":"22","author":"V Morcuende-Ventura","year":"2021","unstructured":"Morcuende-Ventura V, Hermoso-Dur\u00e1n S, Abian-Franco N, Pazo-Cid R, Ojeda JL, Vega S, et al. Fluorescence Liquid Biopsy for Cancer Detection Is Improved by Using Cationic Dendronized Hyperbranched Polymer. Int J Mol Sci. 2021Jun 17;22(12):6501.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3371_CR80","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jmoldx.2015.01.004","volume":"17","author":"G Zhu","year":"2015","unstructured":"Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y, et al. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Mol Diagn. 2015May;17(3):265\u201372.","journal-title":"J Mol Diagn"},{"issue":"4","key":"3371_CR81","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017Apr;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"31","key":"3371_CR82","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1039\/D0TB00861C","volume":"8","author":"B Mart\u00edn-Gracia","year":"2020","unstructured":"Mart\u00edn-Gracia B, Mart\u00edn-Barreiro A, Cuestas-Ayll\u00f3n C, Graz\u00fa V, Line A, Llorente A, et al. Nanoparticle-based biosensors for detection of extracellular vesicles in liquid biopsies. J Mater Chem B. 2020;8(31):6710\u201338.","journal-title":"J Mater Chem B"},{"issue":"6387","key":"3371_CR83","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aar6245","volume":"360","author":"JS Chen","year":"2018","unstructured":"Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018Apr 27;360(6387):436\u20139.","journal-title":"Science"},{"issue":"10","key":"3371_CR84","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1101\/gr.191098.115","volume":"25","author":"NE Navin","year":"2015","unstructured":"Navin NE. The first five years of single-cell cancer genomics and beyond. Genome Res. 2015Oct;25(10):1499\u2013507.","journal-title":"Genome Res"},{"issue":"16","key":"3371_CR85","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1021\/acs.chemrev.6b00220","volume":"116","author":"M Labib","year":"2016","unstructured":"Labib M, Sargent EH, Kelley SO. Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules. Chem Rev. 2016Aug 24;116(16):9001\u201390.","journal-title":"Chem Rev"},{"key":"3371_CR86","doi-asserted-by":"crossref","unstructured":"Liu Y, Liu TY, Weinberg DE, White BW, De La Torre CJ, Tan CL, et al. Spatial co-fragmentation pattern of cell-free DNA recapitulates in vivo chromatin organization and identifies tissues-of-origin [Internet]. Genomics; 2019 [cited 2025 Jan 4]. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/564773","DOI":"10.1101\/564773"},{"issue":"4","key":"3371_CR87","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","volume":"40","author":"MS Esfahani","year":"2022","unstructured":"Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol. 2022Apr;40(4):585\u201397.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3371_CR88","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41467-024-46435-0","volume":"15","author":"KE Stanley","year":"2024","unstructured":"Stanley KE, Jatsenko T, Tuveri S, Sudhakaran D, Lannoo L, Van Calsteren K, et al. Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology. Nat Commun. 2024Mar 12;15(1):2220.","journal-title":"Nat Commun"},{"issue":"3","key":"3371_CR89","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1101\/gr.242719.118","volume":"29","author":"K Sun","year":"2019","unstructured":"Sun K, Jiang P, Cheng SH, Cheng THT, Wong J, Wong VWS, et al. Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Res. 2019Mar;29(3):418\u201327.","journal-title":"Genome Res"},{"key":"3371_CR90","doi-asserted-by":"crossref","unstructured":"Zheng H, Zhu MS, Liu Y. FinaleDB: a browser and database of cell-free DNA fragmentation patterns. Peter R, editor. Bioinformatics. 2021;37(16):2502\u20133.","DOI":"10.1093\/bioinformatics\/btaa999"},{"issue":"1","key":"3371_CR91","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13148-022-01285-9","volume":"14","author":"H Lu","year":"2022","unstructured":"Lu H, Liu Y, Wang J, Fu S, Wang L, Huang C, et al. Detection of ovarian cancer using plasma cell-free DNA methylomes. Clin Epigenetics. 2022Dec;14(1):74.","journal-title":"Clin Epigenetics"},{"key":"3371_CR92","doi-asserted-by":"crossref","unstructured":"Liu Y, Reed SC, Lo C, Choudhury AD, Parsons HA, Stover DG, et al. FinaleMe: Predicting DNA methylation by the fragmentation patterns of plasma cell-free DNA [Internet]. Bioinformatics; 2024 [cited 2025 Jan 4]. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.01.02.573710","DOI":"10.1038\/s41467-024-47196-6"},{"issue":"1","key":"3371_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023Jan;34(1):33\u201347.","journal-title":"Ann Oncol"},{"issue":"10","key":"3371_CR94","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/cancers13102300","volume":"13","author":"HS Ahn","year":"2021","unstructured":"Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, et al. Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1\/2 Carriers. Cancers. 2021May 11;13(10):2300.","journal-title":"Cancers"},{"issue":"4","key":"3371_CR95","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ijc.34318","volume":"152","author":"K Bahar-Shany","year":"2023","unstructured":"Bahar-Shany K, Barnabas GD, Deutsch L, Deutsch N, Glick-Saar E, Dominissini D, et al. Proteomic signature for detection of high-grade ovarian cancer in germline BRCA mutation carriers. Int J Cancer. 2023Feb 15;152(4):781\u201393.","journal-title":"Int J Cancer"},{"issue":"12","key":"3371_CR96","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ijgc-2022-003911","volume":"32","author":"MHD Van Bommel","year":"2022","unstructured":"Van Bommel MHD, Pijnenborg JMA, Van Der Putten LJM, Bulten J, Snijders MPLM, K\u00fcsters-Vandevelde HVN, et al. Diagnostic accuracy of mutational analysis along the M\u00fcllerian tract to detect ovarian cancer. Int J Gynecol Cancer. 2022Dec;32(12):1568\u201375.","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"3371_CR97","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7566","volume":"3","author":"L Paracchini","year":"2020","unstructured":"Paracchini L, Pesenti C, Delle Marchette M, Beltrame L, Bianchi T, Grassi T, et al. Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis. JAMA Netw Open. 2020Jul 1;3(7): e207566.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3371_CR98","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-023-01440-w","volume":"15","author":"SK Terp","year":"2023","unstructured":"Terp SK, Stoico MP, Dybk\u00e6r K, Pedersen IS. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review. Clin Epigenetics. 2023Feb 14;15(1):24.","journal-title":"Clin Epigenetics"},{"key":"3371_CR99","doi-asserted-by":"crossref","unstructured":"Zhou Q, Li W, Leng B, Zheng W, He Z, Zuo M, et al. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis. Chalmers J, editor. PLOS ONE. 2016;11(6):e0155495.","DOI":"10.1371\/journal.pone.0155495"},{"key":"3371_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2019.143993","volume":"714","author":"B Li","year":"2019","unstructured":"Li B, Pu K, Ge L, Wu X. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis. Gene. 2019Sep;714: 143993.","journal-title":"Gene"},{"issue":"1","key":"3371_CR101","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13048-019-0482-8","volume":"12","author":"X Wang","year":"2019","unstructured":"Wang X, Kong D, Wang C, Ding X, Zhang L, Zhao M, et al. Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis. J Ovarian Res. 2019Dec;12(1):24.","journal-title":"J Ovarian Res"},{"issue":"5","key":"3371_CR102","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3390\/biom13050871","volume":"13","author":"NLS Frisk","year":"2023","unstructured":"Frisk NLS, S\u00f8rensen AE, Pedersen OBV, Dalgaard LT. Circulating microRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis. Biomolecules. 2023May 22;13(5):871.","journal-title":"Biomolecules"},{"issue":"3","key":"3371_CR103","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ygyno.2021.04.020","volume":"161","author":"CF Thusgaard","year":"2021","unstructured":"Thusgaard CF, Korsholm M, Koldby KM, Kruse TA, Thomassen M, Jochumsen KM. Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review. Gynecol Oncol. 2021Jun;161(3):884\u201395.","journal-title":"Gynecol Oncol"},{"issue":"22","key":"3371_CR104","doi-asserted-by":"publisher","first-page":"8762","DOI":"10.3390\/ijms21228762","volume":"21","author":"A Lucidi","year":"2020","unstructured":"Lucidi A, Buca D, Ronsini C, Tinari S, Bologna G, Buca D, et al. Role of Extracellular Vesicles in Epithelial Ovarian Cancer: A Systematic Review. Int J Mol Sci. 2020Nov 19;21(22):8762.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3371_CR105","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.annonc.2023.02.010","volume":"34","author":"Q Gao","year":"2023","unstructured":"Gao Q, Lin YP, Li BS, Wang GQ, Dong LQ, Shen BY, et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. Ann Oncol. 2023May;34(5):486\u201395.","journal-title":"Ann Oncol"},{"issue":"3","key":"3371_CR106","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2022.03.018","volume":"165","author":"LM Marinelli","year":"2022","unstructured":"Marinelli LM, Kisiel JB, Slettedahl SW, Mahoney DW, Lemens MA, Shridhar V, et al. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecol Oncol. 2022Jun;165(3):568\u201376.","journal-title":"Gynecol Oncol"},{"key":"3371_CR107","doi-asserted-by":"crossref","unstructured":"Shnaider PV, Petrushanko IYu, Aleshikova OI, Babaeva NA, Ashrafyan LA, Borovkova EI, et al. Expression level of CD117 (KIT) on ovarian cancer extracellular vesicles correlates with tumor aggressiveness. Front Cell Dev Biol. 2023;11:1057484.","DOI":"10.3389\/fcell.2023.1057484"},{"issue":"6","key":"3371_CR108","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.3892\/ol.2015.3771","volume":"10","author":"X Shao","year":"2015","unstructured":"Shao X, He Y, Ji M, Chen X, Qi J, Shi W, et al. Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett. 2015Dec;10(6):3478\u201382.","journal-title":"Oncol Lett"},{"key":"3371_CR109","doi-asserted-by":"crossref","unstructured":"Ogasawara A, Hihara T, Shintani D, Yabuno A, Ikeda Y, Tai K, et al. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations. Cancer Res Treat [Internet]. 2020 May 6 [cited 2025 Jan 4]; Available from: http:\/\/www.e-crt.org\/journal\/view.php?doi=10.4143\/crt.2019.688","DOI":"10.4143\/crt.2019.688"},{"key":"3371_CR110","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.trsl.2023.07.005","volume":"262","author":"L Chen","year":"2023","unstructured":"Chen L, Ma R, Luo C, Xie Q, Ning X, Sun K, et al. Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNA. Transl Res. 2023Dec;262:12\u201324.","journal-title":"Transl Res"},{"issue":"3","key":"3371_CR111","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/cancers15030893","volume":"15","author":"Y Grobben","year":"2023","unstructured":"Grobben Y, Den Ouden JE, Aguado C, Van Altena AM, Kraneveld AD, Zaman GJR. Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1. Cancers. 2023Jan 31;15(3):893.","journal-title":"Cancers"},{"issue":"9","key":"3371_CR112","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3389\/fonc.2019.01015","volume":"15","author":"P Buderath","year":"2019","unstructured":"Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, et al. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. Front Oncol. 2019Oct;15(9):1015.","journal-title":"Front Oncol"},{"key":"3371_CR113","doi-asserted-by":"crossref","unstructured":"Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. Mardis ER, editor. PLOS Med. 2016;13(12):e1002198.","DOI":"10.1371\/journal.pmed.1002198"},{"issue":"14","key":"3371_CR114","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.7150\/thno.34692","volume":"9","author":"L Chang","year":"2019","unstructured":"Chang L, Ni J, Zhu Y, Pang B, Graham P, Zhang H, et al. Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics. 2019;9(14):4130\u201340.","journal-title":"Theranostics"},{"issue":"5","key":"3371_CR115","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/1541-7786.MCR-17-0594","volume":"16","author":"RC Arend","year":"2018","unstructured":"Arend RC, Londo\u00f1o AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, et al. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Mol Cancer Res. 2018May 1;16(5):813\u201324.","journal-title":"Mol Cancer Res"},{"key":"3371_CR116","doi-asserted-by":"crossref","unstructured":"Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. Samimi G, editor. PLOS ONE. 2015;10(12):e0145754.","DOI":"10.1371\/journal.pone.0145754"},{"issue":"10","key":"3371_CR117","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.3390\/cancers13102386","volume":"13","author":"L Paracchini","year":"2021","unstructured":"Paracchini L, D\u2019Incalci M, Marchini S. Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer\u2014Current Use and Future Opportunities. Cancers. 2021May 14;13(10):2386.","journal-title":"Cancers"},{"issue":"6","key":"3371_CR118","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1136\/ijgc-2024-005313","volume":"34","author":"C Taliento","year":"2024","unstructured":"Taliento C, Morciano G, Nero C, Froyman W, Vizzielli G, Pavone M, et al. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2024Jun;34(6):906\u201318.","journal-title":"Int J Gynecol Cancer"},{"issue":"17","key":"3371_CR119","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3390\/diagnostics14171868","volume":"14","author":"A Llueca","year":"2024","unstructured":"Llueca A, Canete-Mota S, Jauregu\u00ed A, Barneo M, Iba\u00f1ez MV, Neef A, et al. The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care. Diagnostics. 2024Aug 26;14(17):1868.","journal-title":"Diagnostics"},{"issue":"19","key":"3371_CR120","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.3390\/cancers14194666","volume":"14","author":"R Karkia","year":"2022","unstructured":"Karkia R, Wali S, Payne A, Karteris E, Chatterjee J. Diagnostic Accuracy of Liquid Biomarkers for the Non-Invasive Diagnosis of Endometrial Cancer: A Systematic Review and Meta-Analysis. Cancers. 2022Sep 25;14(19):4666.","journal-title":"Cancers"},{"key":"3371_CR121","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ygyno.2023.04.014","volume":"174","author":"JN Bakkum-Gamez","year":"2023","unstructured":"Bakkum-Gamez JN, Sherman ME, Slettedahl SW, Mahoney DW, Lemens MA, Laughlin-Tommaso SK, et al. Detection of endometrial cancer using tampon-based collection and methylated DNA markers. Gynecol Oncol. 2023Jul;174:11\u201320.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"3371_CR122","doi-asserted-by":"publisher","first-page":"8683","DOI":"10.3390\/ijms24108683","volume":"24","author":"J Yang","year":"2023","unstructured":"Yang J, Barkley JE, Bhattarai B, Firouzi K, Monk BJ, Coonrod DV, et al. Identification of Endometrial Cancer-Specific microRNA Biomarkers in Endometrial Fluid. Int J Mol Sci. 2023May 12;24(10):8683.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3371_CR123","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/cncr.35381","volume":"130","author":"F Blanc-Durand","year":"2024","unstructured":"Blanc-Durand F, Camilleri GM, Bayle A, Aldea M, Vasseur D, Ouali K, et al. Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer. Cancer. 2024Oct;130(19):3311\u201320.","journal-title":"Cancer"},{"issue":"1","key":"3371_CR124","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13046-024-03158-w","volume":"43","author":"C Casas-Arozamena","year":"2024","unstructured":"Casas-Arozamena C, Vilar A, Cueva J, Arias E, Sampayo V, Diaz E, et al. Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application. J Exp Clin Cancer Res. 2024Sep 20;43(1):264.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"3371_CR125","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.34435","volume":"152","author":"C Casas-Arozamena","year":"2023","unstructured":"Casas-Arozamena C, Moiola CP, Vilar A, Bouso M, Cueva J, Cabrera S, et al. Noninvasive detection of microsatellite instability in patients with endometrial cancer. Int J Cancer. 2023May 15;152(10):2206\u201317.","journal-title":"Int J Cancer"},{"issue":"44","key":"3371_CR126","doi-asserted-by":"publisher","first-page":"17679","DOI":"10.1021\/acs.analchem.4c03726","volume":"96","author":"H Yang","year":"2024","unstructured":"Yang H, Wu P, Li B, Huang X, Shi Q, Qiao L, et al. Diagnosis and Biomarker Screening of Endometrial Cancer Enabled by a Versatile Exosome Metabolic Fingerprint Platform. Anal Chem. 2024Nov 5;96(44):17679\u201388.","journal-title":"Anal Chem"},{"issue":"1","key":"3371_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd EM. Human Papillomavirus and Cervical Cancer. Clin Microbiol Rev. 2003Jan;16(1):1\u201317.","journal-title":"Clin Microbiol Rev"},{"key":"3371_CR128","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jcv.2019.03.005","volume":"114","author":"TH Cheung","year":"2019","unstructured":"Cheung TH, Yim SF, Yu MY, Worley MJ, Fiascone SJ, Chiu RWK, et al. Liquid biopsy of HPV DNA in cervical cancer. J Clin Virol. 2019May;114:32\u20136.","journal-title":"J Clin Virol"},{"issue":"1","key":"3371_CR129","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e1","volume":"30","author":"KH Choi","year":"2019","unstructured":"Choi KH, Lee SW, Yu M, Jeong S, Lee JW, Lee JH. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. J Gynecol Oncol. 2019;30(1): e1.","journal-title":"J Gynecol Oncol"},{"issue":"10","key":"3371_CR130","doi-asserted-by":"publisher","first-page":"837","DOI":"10.21037\/atm-21-87","volume":"9","author":"J Nie","year":"2021","unstructured":"Nie J, Shao J, Guo SW, Liu X. The relevance of plasma R-spondin 1 and Slit2 as predictive biomarkers in cervical cancer chemotherapy and radiotherapy. Ann Transl Med. 2021May;9(10):837\u2013837.","journal-title":"Ann Transl Med"},{"issue":"6","key":"3371_CR131","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3892\/mco.2016.1055","volume":"5","author":"P Moreno-Acosta","year":"2016","unstructured":"Moreno-Acosta P, Carrillo S, Gamboa O, Romero-Rojas A, Acosta J, Molano M, et al. Novel predictive biomarkers for cervical cancer prognosis. Mol Clin Oncol. 2016Dec;5(6):792\u20136.","journal-title":"Mol Clin Oncol"},{"issue":"19","key":"3371_CR132","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.2011.37.5923","volume":"30","author":"S Kang","year":"2012","unstructured":"Kang S, Nam BH, Park JY, Seo SS, Ryu SY, Kim JW, et al. Risk Assessment Tool for Distant Recurrence After Platinum-Based Concurrent Chemoradiation in Patients With Locally Advanced Cervical Cancer: A Korean Gynecologic Oncology Group Study. J Clin Oncol. 2012Jul 1;30(19):2369\u201374.","journal-title":"J Clin Oncol"},{"key":"3371_CR133","doi-asserted-by":"publisher","first-page":"153303382110446","DOI":"10.1177\/15330338211044626","volume":"20","author":"G Zhang","year":"2021","unstructured":"Zhang G, Miao L, Wu H, Zhang Y, Fu C. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy. Technol Cancer Res Treat. 2021Jan;20:15330338211044626.","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"3371_CR134","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3802\/jgo.2013.24.4.313","volume":"24","author":"R Kawaguchi","year":"2013","unstructured":"Kawaguchi R, Furukawa N, Kobayashi H, Asakawa I. Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy. J Gynecol Oncol. 2013;24(4):313.","journal-title":"J Gynecol Oncol"},{"issue":"5","key":"3371_CR135","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5468\/ogs.2015.58.5.368","volume":"58","author":"HK Ryu","year":"2015","unstructured":"Ryu HK, Baek JS, Kang WD, Kim SM. The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients. Obstet Gynecol Sci. 2015;58(5):368.","journal-title":"Obstet Gynecol Sci"},{"issue":"9","key":"3371_CR136","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1002\/ijc.32295","volume":"145","author":"J Tian","year":"2019","unstructured":"Tian J, Geng Y, Lv D, Li P, Cordova M, Liao Y, et al. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer. Int J Cancer. 2019Nov;145(9):2547\u201357.","journal-title":"Int J Cancer"},{"key":"3371_CR137","doi-asserted-by":"crossref","unstructured":"Wen YF, Cheng TT, Chen XL, Huang WJ, Peng HH, Zhou TC, et al. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. Katoh M, editor. PLOS ONE. 2018;13(10):e0204334.","DOI":"10.1371\/journal.pone.0204334"},{"issue":"20","key":"3371_CR138","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033820","volume":"102","author":"K Zhao","year":"2023","unstructured":"Zhao K, Hu M, Yang R, Liu J, Zeng P, Zhao T. Decreasing expression of HIF-1\u03b1, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer. Medicine (Baltimore). 2023May 19;102(20): e33820.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3371_CR139","first-page":"3","volume":"11","author":"SM Dong","year":"2002","unstructured":"Dong SM, Pai SI, Rha SH, Hildesheim A, Kurman RJ, Schwartz PE, et al. Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2002Jan;11(1):3\u20136.","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"S1","key":"3371_CR140","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.21037\/atm.2018.11.31","volume":"6","author":"Y Bai","year":"2018","unstructured":"Bai Y, Zhao H. Liquid biopsy in tumors: opportunities and challenges. Ann Transl Med. 2018Nov;6(S1):S89\u2013S89.","journal-title":"Ann Transl Med"},{"issue":"12","key":"3371_CR141","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1038\/s41379-021-00880-0","volume":"34","author":"LH Lin","year":"2021","unstructured":"Lin LH, Allison DHR, Feng Y, Jour G, Park K, Zhou F, et al. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas. Mod Pathol. 2021Dec;34(12):2168\u201374.","journal-title":"Mod Pathol"},{"issue":"2","key":"3371_CR142","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","volume":"24","author":"LE Raez","year":"2023","unstructured":"Raez LE, Brice K, Dumais K, Lopez-Cohen A, Wietecha D, Izquierdo PA, et al. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2023Mar;24(2):120\u20139.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"3371_CR143","doi-asserted-by":"publisher","first-page":"744","DOI":"10.7150\/jca.66567","volume":"13","author":"S Xie","year":"2022","unstructured":"Xie S, Wang Y, Gong Z, Li Y, Yang W, Liu G, et al. Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC\/FISH for HER2 Amplification Detection in Breast Cancer Patients. J Cancer. 2022;13(3):744\u201351.","journal-title":"J Cancer"},{"issue":"7","key":"3371_CR144","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/diagnostics13071241","volume":"13","author":"C Mazzitelli","year":"2023","unstructured":"Mazzitelli C, Santini D, Corradini AG, Zamagni C, Trer\u00e8 D, Montanaro L, et al. Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going. Diagnostics. 2023Mar 25;13(7):1241.","journal-title":"Diagnostics"},{"issue":"10","key":"3371_CR145","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s12094-018-1855-y","volume":"20","author":"E Arriola","year":"2018","unstructured":"Arriola E, Paredes-Lario A, Garc\u00eda-Gomez R, Diz-Tain P, Constenla M, Garc\u00eda-Gir\u00f3n C, et al. Comparison of plasma ctDNA and tissue\/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin Transl Oncol. 2018Oct;20(10):1261\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"3371_CR146","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","volume":"25","author":"AR Parikh","year":"2019","unstructured":"Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019Sep;25(9):1415\u201321.","journal-title":"Nat Med"},{"issue":"7","key":"3371_CR147","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3390\/cancers14071728","volume":"14","author":"F Ionescu","year":"2022","unstructured":"Ionescu F, Zhang J, Wang L. Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker. Cancers. 2022Mar 29;14(7):1728.","journal-title":"Cancers"},{"issue":"1","key":"3371_CR148","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol OncolJ Hematol Oncol. 2022Sep 12;15(1):131.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"10425","key":"3371_CR149","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(23)02830-1","volume":"403","author":"C Turnbull","year":"2024","unstructured":"Turnbull C, Wald N, Sullivan R, Pharoah P, Houlston RS, Aggarwal A, et al. GRAIL-Galleri: why the special treatment? The Lancet. 2024Feb 3;403(10425):431\u20132.","journal-title":"The Lancet"},{"key":"3371_CR150","unstructured":"Multi-cancer Early Detection Tests | MCED | GRAIL Galleri Test [Internet]. [cited 2025 Mar 8]. Available from: https:\/\/www.cancer.org\/cancer\/screening\/multi-cancer-early-detection-tests.html"}],"updated-by":[{"DOI":"10.1186\/s13046-025-03429-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03371-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T03:02:48Z","timestamp":1748574168000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03371-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3371"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03371-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the authors identified spelling, grammar, and typo errors in the body of the article","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-025-03429-0","URL":"https:\/\/doi.org\/10.1186\/s13046-025-03429-0","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required as this manuscript doesn\u2019t include details, images or videos related to the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}